Acalabrutinib in CNSL

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021
This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).
Epistemonikos ID: f0bf5fb90c5e26a0a48b93441c2bae344f77d2e9
First added on: May 08, 2024